Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Making a noteworthy insider sell on March 20, Jeffrey R. Stewart, EVP at AbbVie (NYSE:ABBV), is reported in the latest SEC filing.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Stewart executed a sale of 58,949 shares of AbbVie with a total value of $10,539,508.
Monitoring the market, AbbVie's shares up by 0.57% at $177.27 during Thursday's morning.
Delving into AbbVie's Background AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Understanding the Numbers: AbbVie's Finances Decline in Revenue: Over the 3 months period, AbbVie faced challenges, resulting in a decline of approximately -5.42% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics:
- Gross Margin: The company shows a low gross margin of 60.11%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
- Earnings per Share (EPS): AbbVie's EPS is below the industry average. The company faced challenges with a current EPS of 0.465474. This suggests a potential decline in earnings.
Insights into Valuation Metrics:
- Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 64.81 suggests caution, as the stock may be overvalued in the eyes of investors.
- Price to Sales (P/S) Ratio: The P/S ratio of 5.75 is lower than the industry average, implying a discounted valuation for AbbVie's stock in relation to sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): AbbVie's EV/EBITDA ratio stands at 20.89, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Exploring the Significance of Insider Trading While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
Transaction Codes To Focus On Delving into transactions, investors typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of AbbVie's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.